Osimertinib (Tagrisso) — 3rd-Generation TKI for EGFR-Mutated Lung Cancer
July 04, 2026
Osimertinib is a 3rd-generation tyrosine kinase inhibitor (TKI) targeting EGFR mutations, including the resistance mutation T790M. Widely used in lung cancer treatment in China.
Mechanism and Advantage
Osimertinib (Tagrisso) is a 3rd-generation TKI targeting EGFR mutations — including ex19del, L858R and especially T790M (the resistance mutation against 1st/2nd-generation TKIs). The drug also crosses the blood-brain barrier, providing efficacy against brain metastases — a major challenge in EGFR+ lung cancer.
Indications and Practice
Used in EGFR+ non-small cell lung cancer (NSCLC) in both early stages (adjuvant post-surgery) and advanced/metastatic disease. In China, EGFR mutation testing is a mandatory step in standard lung cancer treatment protocols.
In China
Lung cancer is prevalent in China and EGFR mutation rates are higher than in Western populations. Hospitals like HYGEIA have extensive experience treating EGFR+ lung cancer with Osimertinib and newer-generation TKIs. International patients in China typically undergo comprehensive next-generation sequencing (NGS) for appropriate drug selection.
Disclaimer
Information is for reference only. The physician determines the protocol after genetic testing.
Related Images
